Log in

ASX:MXCMGC Pharmaceuticals Stock Price, Forecast & News

Today's Range N/A
50-Day Range
MA: A$0.03
52-Week Range N/A
Volume2.16 million shs
Average VolumeN/A
Market Capitalization$23.23 million
P/E RatioN/A
Dividend YieldN/A
MGC Pharmaceuticals Limited, a biopharmaceutical company, produces and supplies medicinal cannabis products in Australia, Slovenia, and other European countries. It is developing phytocannabinoid as active pharmaceutical ingredients (API) for medicinal cannabis products. The company offers MGC MX201 for relief from nausea, vomiting, pain related to chemotherapy treatment, and Tourette syndrome disorder; and MGC MX21 for acquired immunodeficiency syndrome (AIDS), weight loss CAC, and the enhancement of appetite or relief from gastrointestinal vomiting and symptoms, and Parkinson's disease. It also offers MGC MX11 for neuropathy, multiple sclerosis, and Tourette syndrome; and MGC MX120 for epilepsy, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and post-traumatic stress disorder. In addition, the company provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; CannEpil and CannEKids for refractory epilepsy; and TopiCann for anti-inflammatory topical treatment. Further, it offers MGC CBD for anti-inflammatory, antioxidant, neuroprotector, anxiolytic, analgesic, antidepressant, anti-psychotic, and anti-tumoral agent; and MGC THC for nausea and vomiting associated with cancer medicines, as well as enhance the appetite of people with AIDS. Additionally, the company offers nutraceuticals, including CBD cosmetics and hempenhanced products for retail customers online. MGC Pharmaceuticals Limited has a collaboration with Epilepsy Action Australia to create an online platform for providing information and education on medicinal cannabis and epilepsy; and partnership with the Royal Melbourne Institute of Technology and The Hebrew University of Jerusalem to form a medical research hub for medicinal cannabis technologies. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.34 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Phone61 8 6382 3390



Sales & Book Value

Annual Sales$2.15 million
Book ValueA$0.00 per share



Outstanding Shares1,575,609,984
Market Cap$23.23 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MXC News and Ratings via Email

Sign-up to receive the latest news and ratings for MXC and its competitors with MarketBeat's FREE daily newsletter.

MGC Pharmaceuticals (ASX:MXC) Frequently Asked Questions

How were MGC Pharmaceuticals' earnings last quarter?

MGC Pharmaceuticals Ltd (ASX:MXC) released its quarterly earnings results on Thursday, February, 28th. The company reported $0.00 EPS for the quarter. View MGC Pharmaceuticals' earnings history.

Has MGC Pharmaceuticals been receiving favorable news coverage?

News coverage about MXC stock has been trending neutral on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MGC Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about MGC Pharmaceuticals.

Who are some of MGC Pharmaceuticals' key competitors?

What other stocks do shareholders of MGC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MGC Pharmaceuticals investors own include Triton Minerals (TON), Rox Resources (RXL), Northern Minerals (NTU), Medlab Clinical (MDC), Laneway Resources (LNY), iSignthis (ISX), Intel (INTC), BOD Australia (BDA), Azure Minerals (AZS) and Auscann Group (AC8).

Who are MGC Pharmaceuticals' key executives?

MGC Pharmaceuticals' management team includes the following people:
  • Mr. Brett Anthony Mitchell, Exec. Chairman (Age 46)
  • Mr. Roby Reuven Zomer, Co-Founder, CEO, MD & Exec. Director
  • Mr. Nativ Segev, Co-Founder, Head of Bus. Strategy & Exec. Director
  • Ms. Rachel Jelleff Kerr, Company Sec.
  • Hugh Winters, Chief Exec. Officer of MGC Derma

What is MGC Pharmaceuticals' stock symbol?

MGC Pharmaceuticals trades on the ASX under the ticker symbol "MXC."

How big of a company is MGC Pharmaceuticals?

MGC Pharmaceuticals has a market capitalization of $0.00 and generates $2.15 million in revenue each year.

What is MGC Pharmaceuticals' official website?

The official website for MGC Pharmaceuticals is www.mgcpharma.com.au.

How can I contact MGC Pharmaceuticals?

The company can be reached via phone at 61 8 6382 3390.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.